# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances
0, Journal, 0, 23, "Diabetes Technol Ther .", "", "<http://ctro/data#Publication_61653> <http://ctro/data#hasJournal> \"Diabetes Technol Ther .\"."
1, PublicationYear, 24, 28, "2014", "", "<http://ctro/data#Publication_61653> <http://ctro/data#hasPublicationYear> \"2014\"."
88, Liraglutide, 115, 126, "Liraglutide", "", 
20, Title, 115, 286, "Liraglutide ' s safety , tolerability , pharmacokinetics , and pharmacodynamics in pediatric type 2 diabetes : a randomized , double - blind , placebo - controlled trial .", "", "<http://ctro/data#Publication_61653> <http://ctro/data#hasTitle> \"Liraglutide ' s safety , tolerability , pharmacokinetics , and pharmacodynamics in pediatric type 2 diabetes : a randomized , double - blind , placebo - controlled trial .\"."
8, Type2Diabetes, 208, 223, "type 2 diabetes", "", "<http://ctro/data#ClinicalTrial_61660> <http://ctro/data#analysesHealthCondition> <http://ctro/data#Type2Diabetes>."
13, Randomized, 228, 238, "randomized", "", "<http://ctro/data#ClinicalTrial_61660> <http://ctro/data#hasCTDesign> <http://ctro/data#Randomized>."
14, DoubleBlind, 241, 255, "double - blind", "", "<http://ctro/data#ClinicalTrial_61660> <http://ctro/data#hasCTDesign> <http://ctro/data#DoubleBlind>."
15, Placebo, 258, 265, "placebo", "", 
21, Author, 287, 295, "Klein DJ", "", "<http://ctro/data#Publication_61653> <http://ctro/data#hasAuthor> \"Klein DJ\"."
22, Author, 304, 315, "Battelino T", "", "<http://ctro/data#Publication_61653> <http://ctro/data#hasAuthor> \"Battelino T\"."
23, Author, 318, 331, "Chatterjee DJ", "", "<http://ctro/data#Publication_61653> <http://ctro/data#hasAuthor> \"Chatterjee DJ\"."
24, Author, 334, 345, "Jacobsen LV", "", "<http://ctro/data#Publication_61653> <http://ctro/data#hasAuthor> \"Jacobsen LV\"."
25, Author, 348, 355, "Hale PM", "", "<http://ctro/data#Publication_61653> <http://ctro/data#hasAuthor> \"Hale PM\"."
26, Author, 358, 369, "Arslanian S", "", "<http://ctro/data#Publication_61653> <http://ctro/data#hasAuthor> \"Arslanian S\"."
27, USA, 718, 722, "Ohio", "", "<http://ctro/data#Population_61676> <http://ctro/data#hasCountry> <http://ctro/data#USA>."
9, Type2Diabetes, 756, 771, "type 2 diabetes", "", 
10, Type2Diabetes, 774, 777, "T2D", "", 
28, Metformin, 830, 839, "metformin", "", 
29, Insulin, 844, 851, "insulin", "", 
36, ObjectiveDescription, 865, 1080, "The safety , tolerability , pharmacokinetics , and pharmacodynamics of liraglutide once daily in youth ( 10 - 17 years old ) with T2D were investigated in a randomized , double - blind , placebo - controlled trial .", "", "<http://ctro/data#ClinicalTrial_61660> <http://ctro/data#hasObjectiveDescription> \"The safety , tolerability , pharmacokinetics , and pharmacodynamics of liraglutide once daily in youth ( 10 - 17 years old ) with T2D were investigated in a randomized , double - blind , placebo - controlled trial .\"."
104, Liraglutide, 936, 947, "liraglutide", "", 
30, Frequency, 948, 958, "once daily", "", 
76187, Precondition, 962, 967, "youth", "", "<http://ctro/data#Population_61676> <http://ctro/data#hasPrecondition> \"youth\". <http://ctro/data#Population_61676> <http://ctro/data#hasPrecondition> \"with T2D\"."
31, MinAge, 970, 972, "10", "", "<http://ctro/data#Population_61676> <http://ctro/data#hasMinAge> \"10\"."
32, MaxAge, 975, 977, "17", "", "<http://ctro/data#Population_61676> <http://ctro/data#hasMaxAge> \"17\"."
108, Year, 978, 983, "years", "", 
76187, Precondition, 990, 998, "with T2D", "", 
11, Type2Diabetes, 995, 998, "T2D", "", 
33, Randomized, 1022, 1032, "randomized", "", 
34, DoubleBlind, 1035, 1049, "double - blind", "", 
35, Placebo, 1052, 1059, "placebo", "", 
42, Precondition, 1104, 1222, "Youth treated with diet / exercise alone or with metformin and having a hemoglobin A1c ( HbA1c ) level of 6 . 5 - 11 %", "", "<http://ctro/data#Population_61676> <http://ctro/data#hasPrecondition> \"Youth treated with diet / exercise alone or with metformin and having a hemoglobin A1c ( HbA1c ) level of 6 . 5 - 11 %\"."
37, Metformin, 1153, 1162, "metformin", "", 
38, HbA1c, 1176, 1190, "hemoglobin A1c", "", 
39, HbA1c, 1193, 1198, "HbA1c", "", 
41, Percentage, 1221, 1222, "%", "", 
43, Randomized, 1228, 1238, "randomized", "", 
120, Liraglutide, 1242, 1253, "liraglutide", "", "<http://ctro/data#Medication_61714> <http://ctro/data#hasDrug> <http://ctro/data#Liraglutide>."
44, NumberPatientsArm, 1260, 1262, "14", "", "<http://ctro/data#Arm_61684> <http://ctro/data#hasNumberPatientsArm> \"14\"."
18, Placebo, 1268, 1275, "placebo", "", 
45, NumberPatientsArm, 1282, 1283, "7", "", "<http://ctro/data#Arm_61693> <http://ctro/data#hasNumberPatientsArm> \"7\"."
100514, DoseDescription, 1288, 1390, "Starting at 0 . 3 mg / day , doses were escalated weekly to 0 . 6 , 0 . 9 , 1 . 2 , and 1 . 8 mg / day", "", "<http://ctro/data#Medication_61714> <http://ctro/data#hasDoseDescription> \"Starting at 0 . 3 mg / day , doses were escalated weekly to 0 . 6 , 0 . 9 , 1 . 2 , and 1 . 8 mg / day\"."
127, DoseValue, 1300, 1305, "0 . 3", "", 
76181, mg, 1306, 1308, "mg", "", "<http://ctro/data#Medication_61714> <http://ctro/data#hasDoseUnit> <http://ctro/data#mg>."
100519, Frequency, 1311, 1314, "day", "", "<http://ctro/data#Intervention_61702> <http://ctro/data#hasFrequency> \"day\"."
129, DoseValue, 1348, 1353, "0 . 6", "", 
130, DoseValue, 1356, 1361, "0 . 9", "", 
131, DoseValue, 1364, 1369, "1 . 2", "", 
46, DoseValue, 1376, 1381, "1 . 8", "", 
48, mg, 1382, 1384, "mg", "", 
100518, Frequency, 1387, 1390, "day", "", 
16, Placebo, 1396, 1403, "placebo", "", 
51, Duration, 1421, 1428, "5 weeks", "", "<http://ctro/data#ClinicalTrial_61660> <http://ctro/data#hasCTduration> \"5 weeks\"."
52, FinalNumPatientsCT, 1441, 1449, "Nineteen", "", "<http://ctro/data#ClinicalTrial_61660> <http://ctro/data#hasFinalNumberPatientsCT> \"Nineteen\"."
137, TimePoint, 1485, 1493, "Baseline", "", 
138, Mean, 1545, 1549, "mean", "", 
54, AvgAge, 1575, 1581, "14 . 8", "", "<http://ctro/data#Population_61676> <http://ctro/data#hasAvgAge> \"14 . 8\"."
151, Year, 1592, 1597, "years", "", 
55, BodyWeight, 1600, 1606, "weight", "", 
60, BaseLineValue, 1610, 1617, "113 . 2", "", 
148, SdDevBL, 1620, 1626, "35 . 6", "", 
57, Kg, 1629, 1631, "kg", "", 
58, Kg, 1651, 1653, "kg", "", 
150, Year, 1695, 1700, "years", "", 
62, HbA1c, 1707, 1712, "HbA1c", "", 
61, BaseLineValue, 1722, 1727, "8 . 1", "", 
63, Percentage, 1728, 1729, "%", "", 
149, SdDevBL, 1732, 1737, "1 . 2", "", 
65, Percentage, 1738, 1739, "%", "", 
69, ObservedResult, 1744, 1769, "No serious adverse events", "", "<http://ctro/data#Outcome_61765> <http://ctro/data#hasObservedResult> \"No serious adverse events\". <http://ctro/data#Outcome_61792> <http://ctro/data#hasObservedResult> \"No serious adverse events\". <http://ctro/data#Outcome_61819> <http://ctro/data#hasObservedResult> \"No serious adverse events\". <http://ctro/data#Outcome_61846> <http://ctro/data#hasObservedResult> \"No serious adverse events\"."
66, EndPointDescription, 1747, 1769, "serious adverse events", "", "<http://ctro/data#EndPointDescription_61756> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://ctro/data#EndPointDescription>. <http://ctro/data#Endpoint_61755> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#EndPointDescription_61756>."
67, EndPointDescription, 1772, 1775, "AEs", "", 
68, SevereHypoglycemia, 1790, 1809, "severe hypoglycemia", "", "<http://ctro/data#Endpoint_61760> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#SevereHypoglycemia>."
70, GastrointestinalProblem, 1833, 1853, "gastrointestinal AEs", "", "<http://ctro/data#Endpoint_61873> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#GastrointestinalProblem>."
71, ObservedResult, 1854, 1922, "were most common at lower liraglutide doses during dose escalation .", "", "<http://ctro/data#Outcome_61878> <http://ctro/data#hasObservedResult> \"were most common at lower liraglutide doses during dose escalation .\"."
155, Liraglutide, 1880, 1891, "liraglutide", "", 
73, EndPointDescription, 2020, 2032, "pancreatitis", "", 
74, EndPointDescription, 2036, 2042, "lipase", "", 
72, EndPointDescription, 2097, 2107, "calcitonin", "", 
156, Liraglutide, 2154, 2165, "liraglutide", "", 
47, DoseValue, 2166, 2171, "1 . 8", "", 
49, mg, 2172, 2174, "mg", "", 
157, Mean, 2177, 2181, "mean", "", "<http://ctro/data#Mean_61907> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://ctro/data#Mean>. <http://ctro/data#Endpoint_61905> <http://ctro/data#hasAggregationMethod> <http://ctro/data#Mean_61907>."
160, EndPointDescription, 2182, 2193, "half - life", "", "<http://ctro/data#EndPointDescription_61906> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://ctro/data#EndPointDescription>. <http://ctro/data#Endpoint_61905> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#EndPointDescription_61906>."
162, ResultMeasuredValue, 2198, 2200, "12", "", "<http://ctro/data#Outcome_61915> <http://ctro/data#hasResultMeasuredValue> \"12\"."
164, Hour, 2201, 2202, "h", "", "<http://ctro/data#Endpoint_61905> <http://ctro/data#hasBaselineUnit> <http://ctro/data#Hour>."
161, EndPointDescription, 2209, 2218, "clearance", "", "<http://ctro/data#EndPointDescription_61911> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://ctro/data#EndPointDescription>. <http://ctro/data#Endpoint_61910> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#EndPointDescription_61911>."
163, ResultMeasuredValue, 2223, 2228, "1 . 7", "", "<http://ctro/data#Outcome_61942> <http://ctro/data#hasResultMeasuredValue> \"1 . 7\"."
165, BioAndMedicalUnit, 2229, 2234, "L / h", "", "<http://ctro/data#BioAndMedicalUnit_61913> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://ctro/data#BioAndMedicalUnit>. <http://ctro/data#Endpoint_61910> <http://ctro/data#hasBaselineUnit> <http://ctro/data#BioAndMedicalUnit_61913>."
76, TimePoint, 2243, 2250, "5 weeks", "", "<http://ctro/data#Outcome_61979> <http://ctro/data#hasTimePoint> \"5 weeks\". <http://ctro/data#Outcome_62006> <http://ctro/data#hasTimePoint> \"5 weeks\". <http://ctro/data#Outcome_62033> <http://ctro/data#hasTimePoint> \"5 weeks\". <http://ctro/data#Outcome_62060> <http://ctro/data#hasTimePoint> \"5 weeks\"."
40, HbA1c, 2268, 2273, "HbA1c", "", "<http://ctro/data#Endpoint_61969> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#HbA1c>."
168, Liraglutide, 2297, 2308, "liraglutide", "", 
17, Placebo, 2316, 2323, "placebo", "", 
77, Reduction, 2328, 2334, "0 . 86", "", "<http://ctro/data#Outcome_61979> <http://ctro/data#hasChangeValue> \"0 . 86\"."
78, Increment, 2340, 2346, "0 . 04", "", "<http://ctro/data#Outcome_62006> <http://ctro/data#hasChangeValue> \"0 . 04\"."
79, Percentage, 2347, 2348, "%", "", "<http://ctro/data#Endpoint_61969> <http://ctro/data#hasBaselineUnit> <http://ctro/data#Percentage>."
80, PvalueDiff, 2351, 2363, "P = 0 . 0007", "", "<http://ctro/data#DiffBetweenGroups_62096> <http://ctro/data#hasPvalueDiff> \"P = 0 . 0007\"."
174, Mean, 2376, 2380, "mean", "", "<http://ctro/data#Mean_61976> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://ctro/data#Mean>. <http://ctro/data#Endpoint_61974> <http://ctro/data#hasAggregationMethod> <http://ctro/data#Mean_61976>."
56, BodyWeight, 2381, 2392, "body weight", "", "<http://ctro/data#Endpoint_61974> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#BodyWeight>."
81, Reduction, 2413, 2419, "0 . 50", "", "<http://ctro/data#Outcome_62033> <http://ctro/data#hasChangeValue> \"0 . 50\"."
82, Reduction, 2427, 2433, "0 . 54", "", "<http://ctro/data#Outcome_62060> <http://ctro/data#hasChangeValue> \"0 . 54\"."
59, Kg, 2434, 2436, "kg", "", "<http://ctro/data#Endpoint_61974> <http://ctro/data#hasBaselineUnit> <http://ctro/data#Kg>."
83, PvalueDiff, 2439, 2451, "P = 0 . 9703", "", "<http://ctro/data#DiffBetweenGroups_62087> <http://ctro/data#hasPvalueDiff> \"P = 0 . 9703\"."
84, ConclusionComment, 2470, 2610, "Liraglutide was well tolerated in youth with T2D , with safety , tolerability , and pharmacokinetic profiles similar to profiles in adults .", "", "<http://ctro/data#ClinicalTrial_61660> <http://ctro/data#hasConclusionComment> \"Liraglutide was well tolerated in youth with T2D , with safety , tolerability , and pharmacokinetic profiles similar to profiles in adults .\"."
180, Liraglutide, 2470, 2481, "Liraglutide", "", 
12, Type2Diabetes, 2515, 2518, "T2D", "", 
85, PMID, 2673, 2681, "25036533", "", "<http://ctro/data#Publication_61653> <http://ctro/data#hasPMID> \"25036533\"."
